Search

Your search keyword '"Poulsen, Christian"' showing total 741 results
Start Over Author "Poulsen, Christian"
741 results on '"Poulsen, Christian"'

2. Validation of prognostic models in elderly patients with diffuse large B-cell lymphoma in a real-world nationwide population-based study – development of a clinical nomogram

Author

Jelicic, Jelena, Juul-Jensen, Karen, Bukumiric, Zoran, Runason Simonsen, Mikkel, Kragh Jørgensen, Rasmus Rask, Roost Clausen, Michael, Ludvigsen Al-Mashhadi, Ahmed, Schou Pedersen, Robert, Bjørn Poulsen, Christian, Ortved Gang, Anne, Brown, Peter, El-Galaly, Tarec Christoffer, and Stauffer Larsen, Thomas

Published
2024
Full Text
View/download PDF

4. Correction: Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

Author

Lahmer, Tobias, Salmanton-García, Jon, Marchesi, Francesco, El-Ashwah, Shaimaa, Nucci, Marcio, Besson, Caroline, Itri, Federico, Jaksic, Ozren, Čolović, Natasha, Weinbergerová, Barbora, Seval, Guldane Cengiz, Adžić-Vukičević, Tatjana, Szotkowski, Tomáš, Sili, Uluhan, Dargenio, Michelina, van Praet, Jens, van Doesum, Jaap, Schönlein, Martin, Ráčil, Zdeněk, Žák, Pavel, Poulsen, Christian Bjørn, Magliano, Gabriele, Jiménez, Moraima, Bonuomo, Valentina, Piukovics, Klára, Dragonetti, Giulia, Demirkan, Fatih, Blennow, Ola, Valković, Toni, Gomes Da Silva, Maria, Maertens, Johan, Glenthøj, Andreas, Fernández, Noemí, Bergantim, Rui, Verga, Luisa, Petzer, Verena, Omrani, Ali S., Méndez, Gustavo-Adolfo, Machado, Marina, Ledoux, Marie-Pierre, Bailén, Rebeca, Duarte, Rafael F., Del Principe, Maria Ilaria, Farina, Francesca, Martín-Pérez, Sonia, Dávila-Valls, Julio, Marchetti, Monia, Bilgin, Yavuz M., Fracchiolla, Nicola S., Cattaneo, Chiara, Espigado, Ildefonso, Cordoba, Raul, Collins, Graham P., Labrador, Jorge, Falces-Romero, Iker, Prezioso, Lucia, Meers, Stef, Passamonti, Francesco, Buquicchio, Caterina, López-García, Alberto, Kulasekararaj, Austin, Ormazabal-Vélez, Irati, Cuccaro, Annarosa, Garcia-Vidal, Carolina, Busca, Alessandro, Navrátil, Milan, de Jonge, Nick, Biernat, Monika M., Guidetti, Anna, Abu-Zeinah, Ghaith, Samarkos, Michail, Anastasopoulou, Amalia, de Ramón, Cristina, González-López, Tomás José, Hoenigl, Martin, Finizio, Olimpia, Pinczés, László Imre, Ali, Natasha, Vena, Antonio, Tascini, Carlo, Stojanoski, Zlate, Merelli, Maria, Emarah, Ziad, Kohn, Milena, Barać, Aleksandra, Mladenović, Miloš, Mišković, Bojana, Ilhan, Osman, Çolak, Gökçe Melis, Čerňan, Martin, Gräfe, Stefanie K., Ammatuna, Emanuele, Hanakova, Michaela, Víšek, Benjamín, Cabirta, Alba, Nordlander, Anna, Nunes Rodrigues, Raquel, Hersby, Ditte Stampe, Zambrotta, Giovanni Paolo Maria, Wolf, Dominik, Núñez-Martín-Buitrago, Lucía, Arellano, Elena, Aiello, Tommaso Francesco, García-Sanz, Ramón, Prattes, Juergen, Egger, Matthias, Limongelli, Alessandro, Bavastro, Martina, Cvetanoski, Milche, Dibos, Miriam, Rasch, Sebastian, Rahimli, Laman, Cornely, Oliver A., and Pagano, Livio

Published
2024
Full Text
View/download PDF

5. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

Author

Lahmer, Tobias, Salmanton-García, Jon, Marchesi, Francesco, El-Ashwah, Shaimaa, Nucci, Marcio, Besson, Caroline, Itri, Federico, Jaksic, Ozren, Čolović, Natasha, Weinbergerová, Barbora, Seval, Guldane Cengiz, Adžić-Vukičević, Tatjana, Szotkowski, Tomáš, Sili, Uluhan, Dargenio, Michelina, van Praet, Jens, van Doesum, Jaap, Schönlein, Martin, Ráčil, Zdeněk, Žák, Pavel, Poulsen, Christian Bjørn, Magliano, Gabriele, Jiménez, Moraima, Bonuomo, Valentina, Piukovics, Klára, Dragonetti, Giulia, Demirkan, Fatih, Blennow, Ola, Valković, Toni, Gomes Da Silva, Maria, Maertens, Johan, Glenthøj, Andreas, Fernández, Noemí, Bergantim, Rui, Verga, Luisa, Petzer, Verena, Omrani, Ali S., Méndez, Gustavo-Adolfo, Machado, Marina, Ledoux, Marie-Pierre, Bailén, Rebeca, Duarte, Rafael F., Del Principe, Maria Ilaria, Farina, Francesca, Martín-Pérez, Sonia, Dávila-Valls, Julio, Marchetti, Monia, Bilgin, Yavuz M., Fracchiolla, Nicola S., Cattaneo, Chiara, Espigado, Ildefonso, Cordoba, Raul, Collins, Graham P., Labrador, Jorge, Falces-Romero, Iker, Prezioso, Lucia, Meers, Stef, Passamonti, Francesco, Buquicchio, Caterina, López-García, Alberto, Kulasekararaj, Austin, Ormazabal-Vélez, Irati, Cuccaro, Annarosa, Garcia-Vidal, Carolina, Busca, Alessandro, Navrátil, Milan, de Jonge, Nick, Biernat, Monika M., Guidetti, Anna, Abu-Zeinah, Ghaith, Samarkos, Michail, Anastasopoulou, Amalia, de Ramón, Cristina, González-López, Tomás José, Hoenigl, Martin, Finizio, Olimpia, Pinczés, László Imre, Ali, Natasha, Vena, Antonio, Tascini, Carlo, Stojanoski, Zlate, Merelli, Maria, Emarah, Ziad, Kohn, Milena, Barać, Aleksandra, Mladenović, Miloš, Mišković, Bojana, Ilhan, Osman, Çolak, Gökçe Melis, Čerňan, Martin, Gräfe, Stefanie K., Ammatuna, Emanuele, Hanakova, Michaela, Víšek, Benjamín, Cabirta, Alba, Nordlander, Anna, Nunes Rodrigues, Raquel, Hersby, Ditte Stampe, Zambrotta, Giovanni Paolo Maria, Wolf, Dominik, Núñez-Martín-Buitrago, Lucía, Arellano, Elena, Aiello, Tommaso Francesco, García-Sanz, Ramón, Prattes, Juergen, Egger, Matthias, Limongelli, Alessandro, Bavastro, Martina, Cvetanoski, Milche, Dibos, Miriam, Rasch, Sebastian, Rahimli, Laman, Cornely, Oliver A., and Pagano, Livio

Published
2024
Full Text
View/download PDF

7. Designing of an AM Learning Factory Using Interactive Videos as a Didactic Approach

Author

Zhang, Yang, Poulsen, Christian, Liu, Cong, Salling, Lotta Jin Hwa, Kacprzyk, Janusz, Series Editor, Gomide, Fernando, Advisory Editor, Kaynak, Okyay, Advisory Editor, Liu, Derong, Advisory Editor, Pedrycz, Witold, Advisory Editor, Polycarpou, Marios M., Advisory Editor, Rudas, Imre J., Advisory Editor, Wang, Jun, Advisory Editor, Thiede, Sebastian, editor, and Lutters, Eric, editor

Published
2024
Full Text
View/download PDF

11. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Author

Fürstenau, Moritz, Kater, Arnon P, Robrecht, Sandra, von Tresckow, Julia, Zhang, Can, Gregor, Michael, Thornton, Patrick, Staber, Philipp B, Tadmor, Tamar, Lindström, Vesa, Juliusson, Gunnar, Janssens, Ann, Levin, Mark-David, da Cunha-Bang, Caspar, Schneider, Christof, Goldschmidt, Neta, Vandenberghe, Elisabeth, Rossi, Davide, Benz, Rudolf, Nösslinger, Thomas, Heintel, Daniel, Poulsen, Christian B, Christiansen, Ilse, Frederiksen, Henrik, Enggaard, Lisbeth, Posthuma, Eduardus F M, Issa, Djamila E, Visser, Hein P J, Bellido, Mar, Kutsch, Nadine, Dürig, Jan, Stehle, Alexander, Vöhringer, Matthias, Böttcher, Sebastian, Schulte, Clemens, Simon, Florian, Fink, Anna-Maria, Fischer, Kirsten, Holmes, Emily E, Kreuzer, Karl-Anton, Ritgen, Matthias, Brüggemann, Monika, Tausch, Eugen, Stilgenbauer, Stephan, Hallek, Michael, Niemann, Carsten U, and Eichhorst, Barbara

Published
2024
Full Text
View/download PDF

12. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

Author

Martín-Vallejo, Francisco Javier, Zdziarski, Przemyslaw, Zarrinfer, Hossein, Wittig, Jana, Win, Sein, Wai-Man, Vivien, Víšek, Benjamín, Vinh, Donald C., Vehreschild, Maria, Varricchio, Gina, Tsirigotis, Panagiotis, Torres-Tienza, Ana, Tanase, Alina Daniela, Tafuri, Agostino, Stamouli, Maria, Sramek, Jiří, Soussain, Carole, Shirinova, Ayten, Schubert, Jörg, Schalk, Enrico, Salehi, Mohammad Reza, Saleh, Modar, Rosati, Giorgio, Roldán, Elisa, Reizine, Florian, Rêgo, Mayara, Regalado-Artamendi, Isabel, Popova, Marina, Pinto, Fernando, Philippe, Laure, Orth, Hans Martin, Ommen, Hans-Beier, Obr, Aleš, Núñez-Martín-Buitrago, Lucía, Noël, Nicolas, Neuhann, Julia, Nadali, Gianpaolo, Nacov, Julia A., Munhoz Alburquerque, Ana M., Mitra, Maria Enza, Mikulska, Malgorzata, Mellinghoff, Sibylle, Mechtel, Ben, Martín-González, Juan-Alberto, Malak, Sandra, Loureiro-Amigo, Jorge, Lorenzo De La Peña, Lisset, Liberti, Giulia, Landau, Marianne, Lacej, Ira, Kolditz, Martin, Kho, Chi Shan, Khedr, Reham Abdelaziz, Karthaus, Meinolf, Karlsson, Linda Katharina, Jiménez-Lorenzo, María-Josefa, Izuzquiza, Macarena, Hoell-Neugebauer, Baerbel, Herbrecht, Raoul, Heath, Christopher H., Guolo, Fabio, Grothe, Jan, Giordano, Antonio, Gerasymchuk, Sergey, García-Sanz, Ramón, García-Poutón, Nicole, Funke, Vaneuza Araújo Moreira, Fung, Monica, Flasshove, Charlotte, Fianchi, Luana, Essame, Jenna, Egger, Matthias, Drenou, Bernard, Dragonetti, Giulia, Desole, Maximilian, Della Pepa, Roberta, Deau Fischer, Bénédicte, De Kort, Elizabeth, De Cabo, Erik, Danion, François, Daguindau, Etienne, Cushion, Tania, Cremer, Louise, Criscuolo, Marianna, Cordini, Gregorio, Cingolani, Antonella, Ciceri, Fabio, Chowdhury, Fazle Rabbi, Chelysheva, Ekaterina, Chauchet, Adrien, Chai, Louis Yi Ann, Ceesay, M. Mansour, Busch, Elena, Brehon, Mathias, Borducchi, Davimar M.M., Booth, Stephen, Bologna, Serge, Berg Venemyr, Caroline, Bailén-Almorox, Rebeca, Antoniadou, Anastasia, Anastasopoulou, Amalia N., Altuntaş, Fevzi, Salmanton-García, Jon, Marchesi, Francesco, Farina, Francesca, Weinbergerová, Barbora, Itri, Federico, Dávila-Valls, Julio, Martín-Pérez, Sonia, Glenthøj, Andreas, Hersby, Ditte Stampe, Gomes Da Silva, Maria, Nunes Rodrigues, Raquel, López-García, Alberto, Córdoba, Raúl, Bilgin, Yavuz M., Falces-Romero, Iker, El-Ashwah, Shaimaa, Emarah, Ziad, Besson, Caroline, Kohn, Milena, Van Doesum, Jaap, Ammatuna, Emanuele, Marchetti, Monia, Labrador, Jorge, Zambrotta, Giovanni Paolo Maria, Verga, Luisa, Jaksic, Ozren, Nucci, Marcio, Piukovics, Klára, Cabirta-Touzón, Alba, Jiménez, Moraima, Arellano, Elena, Espigado, Ildefonso, Blennow, Ola, Nordlander, Anna, Meers, Stef, Vian Praet, Jens, Aiello, Tommaso Francesco, Garcia-Vidal, Carolina, Fracchiolla, Nicola S., Sciumè, Mariarita, Seval, Guldane Cengiz, Žák, Pavel, Buquicchio, Caterina, Tascini, Carlo, Gräfe, Stefanie K., Schönlein, Martin, Adžić-VUKIČEVIĆ, Tatjana, Bonuomo, Valentina, Cattaneo, Chiara, Nizamuddin, Summiya, Čerňan, Martin, Plantefeve, Gaëtan, Prin, Romane, Szotkovski, Tomas, Collins, Graham P., Dargenio, Michelina, Petzer, Verena, Wolf, Dominik, Čolović, Natasha, Prezioso, Lucia, Valković, Toni, Passamonti, Francesco, Méndez, Gustavo-Adolfo, Sili, Uluhan, Vena, Antonio, Bavastro, Martina, Limongelli, Alessandro, Duarte, Rafael F., Ledoux, Marie-Pierre, Cvetanoski, Milche, Stojanoski, Zlate, Machado, Marina, Batinić, Josip, Magliano, Gabriele, Biernat, Monika M., Pantić, Nikola, Poulsen, Christian Bjørn, Cuccaro, Annarosa, Del Principe, Maria Ilaria, Kulasekararaj, Austin, Ormazabal-Vélez, Irati, Busca, Alessandro, Demirkan, Fatih, Ijaz, Marriyam, Klimko, Nikolai, Stoma, Igor, Khostelidi, Sofya, Fernández, Noemí, Omrani, Ali S., Bergantim, Rui, De Jonge, Nick, Fouquet, Guillemette, Navrátil, Milan, Abu-Zeinah, Ghaith, Samarkos, Michail, Maertens, Johan, De Ramón, Cristina, Guidetti, Anna, Magyari, Ferenc, González-López, Tomás José, Lahmer, Tobias, Finizio, Olimpia, Ali, Natasha, Pinczés, László Imre, Lavilla-Rubira, Esperanza, Romano, Alessandra, Merelli, Maria, Delia, Mario, Calbacho, Maria, Meletiadis, Joseph, Antić, Darko, Hernández-Rivas, José-Ángel, Marques De Almeida, Joyce, Al-Khabori, Murtadha, Hoenigl, Martin, Tisi, Maria Chiara, Khanna, Nina, Barać, Aleksandra, Eisa, Noha, Di Blasi, Roberta, Liévin, Raphaël, Miranda-Castillo, Carolina, Bahr, Nathan C., Lamure, Sylvain, Papa, Mario Virgilio, Yahya, Ayel, Aujayeb, Avinash, Novák, Jan, Erben, Nurettin, Fernández-Galán, María, Ribera-Santa Susana, José-María, Rinaldi, Ikhwan, Fazzi, Rita, Piedimonte, Monica, Duléry, Rémy, Gonzaga, Yung, Soto-Silva, Andrés, Sapienza, Giuseppe, Serris, Alexandra, Drgoňa, Ľuboš, Groh, Ana, Serrano, Laura, Gavriilaki, Eleni, Tragiannidis, Athanasios, Prattes, Juergen, Coppola, Nicola, Otašević, Vladimir, Mladenović, Miloš, Mitrović, Mirjana, Mišković, Bojana, Jindra, Pavel, Zompi, Sofia, Sacchi, Maria Vittoria, Krekeler, Carolin, Shumilov, Evgenii, Infante, Maria Stefania, García-Bordallo, Daniel, Çolak, Gökçe Melis, Mayer, Jiří, Nygaard, Marietta, Hanáková, Michaela, Ráčil, Zdeněk, Quattrone, Martina, Bonanni, Matteo, Koehler, Philipp, Rahimli, Laman, Cornely, Oliver A., and Pagano, Livio

Published
2024
Full Text
View/download PDF

13. SciNote: Collaborative Problem Solving and Argumentation Tool

Author

Rafner, Janet, Hjorth, Arthur, Weidner, Carrie, Ahmed, Shaeema Zaman, Poulsen, Christian, Klokmose, Clemens, and Sherson, Jacob

Subjects
Computer Science - Computers and Society, Computer Science - Human-Computer Interaction
Abstract

As educators push for students to learn science by doing science, there is a need for computational scaffolding to assist students' evaluation of scientific evidence and argument building. In this paper, we present a pilot study of SciNote, a CSCL tool allowing educators to integrate third-party software into a flexible and collaborative workspace. We explore how SciNote enables teams to build data-driven arguments during inquiry-based learning activities., Comment: International Society of the Learning Sciences

Published
2021

14. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Author

Pagano, Livio, Salmanton-García, Jon, Marchesi, Francesco, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolai, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Verga, Luisa, Víšek, Benjamin, Ilhan, Osman, Nadali, Gianpaolo, Weinbergerová, Barbora, Córdoba-Mascuñano, Raúl, Marchetti, Monia, Collins, Graham P, Farina, Francesca, Cattaneo, Chiara, Cabirta, Alba, Gomes-Silva, Maria, Itri, Federico, van Doesum, Jaap, Ledoux, Marie-Pierre, Čerňan, Martin, Jakšić, Ozren, Duarte, Rafael F, Magliano, Gabriele, Omrani, Ali S, Fracchiolla, Nicola S, Kulasekararaj, Austin, Valković, Toni, Poulsen, Christian Bjørn, Machado, Marina, Glenthøj, Andreas, Stoma, Igor, Ráčil, Zdeněk, Piukovics, Klára, Navrátil, Milan, Emarah, Ziad, Sili, Uluhan, Maertens, Johan, Blennow, Ola, Bergantim, Rui, García-Vidal, Carolina, Prezioso, Lucia, Guidetti, Anna, del Principe, Maria Ilaria, Popova, Marina, de Jonge, Nick, Ormazabal-Vélez, Irati, Fernández, Noemí, Falces-Romero, Iker, Cuccaro, Annarosa, Meers, Stef, Buquicchio, Caterina, Antić, Darko, Al-Khabori, Murtadha, García-Sanz, Ramón, Biernat, Monika M, Tisi, Maria Chiara, Sal, Ertan, Rahimli, Laman, Čolović, Natasa, Schönlein, Martin, Calbacho, Maria, Tascini, Carlo, Miranda-Castillo, Carolina, Khanna, Nina, Méndez, Gustavo-Adolfo, Petzer, Verena, Novák, Jan, Besson, Caroline, Duléry, Rémy, Lamure, Sylvain, Nucci, Marcio, Zambrotta, Giovanni, Žák, Pavel, Seval, Guldane Cengiz, Bonuomo, Valentina, Mayer, Jiří, López-García, Alberto, Sacchi, Maria Vittoria, Booth, Stephen, Ciceri, Fabio, Oberti, Margherita, Salvini, Marco, Izuzquiza, Macarena, Nunes-Rodrigues, Raquel, Ammatuna, Emanuele, Obr, Aleš, Herbrecht, Raoul, Núñez-Martín-Buitrago, Lucía, Mancini, Valentina, Shwaylia, Hawraa, Sciumè, Mariarita, Essame, Jenna, Nygaard, Marietta, and Batinić, Josip

Subjects
Prevention, Cancer, Lymphoma, Rare Diseases, Hematology, Good Health and Well Being, Adult, Aged, Aged, 80 and over, COVID-19, Europe, Female, Hematologic Neoplasms, Hospitalization, Humans, Intensive Care Units, Male, Middle Aged, Registries, Risk Factors, SARS-CoV-2, Young Adult, Pandemic, Hematological malignancies, Epidemiology, EHA, EPICOVIDEHA working group, Cardiorespiratory Medicine and Haematology, Oncology and Carcinogenesis
Abstract

BackgroundPatients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality.MethodsThe survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020.ResultsThe study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March-May 2020) and the second wave (October-December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value

Published
2021

19. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings

Author

MARQUES DE ALMEIDA, Joyce, HERNÁNDEZ-RIVAS, José-Ángel, GUIDETTI, Anna, FINIZIO, Olimpia, STOJANOSKI, Zlate, CVETANOSKI, Milche, MELETIADIS, Joseph, DE JONGE, Nick, ANTIĆ, Darko, ALI, Natasha, TISI, Maria Chiara, SERRANO, Laura, PLANTEFEVE, Gaëtan, KHANNA, Nina, HOENIGL, Martin, ČERŇAN, Martin, MIRANDA-CASTILLO, Carolina, FERNÁNDEZ-GALÁN, María, SERRIS, Alexandra, ERBEN, Nurettin, DULÉRY, Rémy, AUJAYEB, Avinash, PAPA, Mario Virgilio, NOVÁK, Jan, DELIA, Mario, SAPIENZA, Giuseppe, REIZINE, Florian, OMRANI, Ali S., DI BLASI, Roberta, LAMURE, Sylvain, DRGOŇA, Ľuboš, COPPOLA, Nicola, BATINIĆ, Josip, AL-KHABORI, Murtadha, RIBERA-SANTA SUSANA, José-María, PIEDIMONTE, Monica, LOUREIRO-AMIGO, Jorge, FOUQUET, Guillemette, FAZZI, Rita, DANION, François, SCHUBERT, Jörg, HOELL-NEUGEBAUER, Baerbel, BAHR, Nathan C., YAHIA, Ayel Omar, TORRES-ATIENZA, Ana, RINALDI, Ikhwan, POPOVA, Marina, OMMEN, Hans-Beier, MITRA, Maria Enza, MIKULSKA, Malgorzata, LACEJ, Ira, KHOSTELIDI, Sofya, WIN, Sein, VINH, Donald, SALEH, Modar, PRATTES, Juergen, JINDRA, Pavel, GUOLO, Fabio, DELLA PEPA, Roberta, CHELYSHEVA, Ekaterina, ZDZIARSKI, Przemyslaw, WAI-MAN, Vivien, SOTO-SILVA, Andrés, ORTH, Hans Martin, MALAK, Sandra, LORENZO DE LA PEÑA, Lisset, KOLDITZ, Martin, Shan KHO, Chi, HEATH, Christopher H., GROH, Ana, GAVRIILAKI, Eleni, FUNG, Monica, EGGER, Matthias, DE KORT, Elizabeth, DE CABO, Erik, CUSHION, Tania, CHOWDHURY, Fazle Rabbi, CEESAY, M. Mansour, BREHON, Mathias, VARRICCHIO, Gina, TAFURI, Agostino, JIMÉNEZ-LORENZO, María-Josefa, KLIMKO, Nikolai, TSIRIGOTIS, Panagiotis, ANTONIADOU, Anastasia, VEHRESCHILD, Maria, Rossi, Giuseppe, Salmanton-García, Jon, Cattaneo, Chiara, Marchesi, Francesco, Dávila-Valls, Julio, Martín-Pérez, Sonia, Itri, Federico, López-García, Alberto, Glenthøj, Andreas, Gomes da Silva, Maria, Besson, Caroline, Marchetti, Monia, Weinbergerová, Barbora, Jaksic, Ozren, Jiménez, Moraima, Bilgin, Yavuz M., Van Doesum, Jaap, Farina, Francesca, Žák, Pavel, Verga, Luisa, Collins, Graham P., Bonuomo, Valentina, Van Praet, Jens, Nucci, Marcio, Meers, Stef, Espigado, Ildefonso, Fracchiolla, Nicola S., Valković, Toni, Poulsen, Christian Bjørn, Čolović, Natasha, Dragonetti, Giulia, Ledoux, Marie-Pierre, Tascini, Carlo, Buquicchio, Caterina, Blennow, Ola, Passamonti, Francesco, Machado, Marina, Labrador, Jorge, Duarte, Rafael F., Schönlein, Martin, Prezioso, Lucia, Falces-Romero, Iker, Kulasekararaj, Austin, Garcia-Vidal, Carolina, Fernández, Noemí, Abu-Zeinah, Ghaith, Ormazabal-Vélez, Irati, Adžić-Vukičević, Tatjana, Piukovics, Klára, Stoma, Igor, Cuccaro, Annarosa, Magliano, Gabriele, Szotkowski, Tomáš, González-López, Tomás-José, El-Ashwah, Shaimaa, Bergantim, Rui, Sili, Uluhan, Maertens, Johan, Demirkan, Fatih, De Ramón, Cristina, Petzer, Verena, Del Principe, Maria Ilaria, Navrátil, Milan, Dargenio, Michelina, Seval, Guldane Cengiz, Samarkos, Michail, Ráčil, Zdeněk, Pinczés, László Imre, Lahmer, Tobias, Busca, Alessandro, Méndez, Gustavo-Adolfo, Vena, Antonio, Biernat, Monika M., Merelli, Maria, Calbacho, Maria, Barać, Aleksandra, Bavastro, Martina, Limongelli, Alessandro, Ilhan, Osman, Wolf, Dominik, Çolak, Gökçe Melis, García-Sanz, Ramón, Emarah, Ziad, Mišković, Bojana, Gräfe, Stefanie K., Mladenović, Miloš, Aiello, Tommaso Francesco, Núñez-Martín-Buitrago, Lucía, Nordlander, Anna, Arellano, Elena, Zambrotta, Giovanni Paolo Maria, Ammatuna, Emanuele, Cabirta, Alba, Sacchi, Maria Vittoria, Nunes Rodrigues, Raquel, Hersby, Ditte Stampe, Hanakova, Michaela, Rahimli, Laman, Cordoba, Raul, Cornely, Oliver A., and Pagano, Livio

Published
2023
Full Text
View/download PDF

20. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Author

Fürstenau, Moritz, Thus, Yvonne J., Robrecht, Sandra, Mellink, Clemens H. M., van der Kevie-Kersemaekers, Anne-Marie, Dubois, Julie, von Tresckow, Julia, Patz, Michaela, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, da Cunha-Bang, Caspar, Schneider, Christof, Poulsen, Christian Bjoern, Illmer, Thomas, Schöttker, Björn, Janssens, Ann, Christiansen, Ilse, Nösslinger, Thomas, Baumann, Michael, Hebart, Holger, Gaska, Tobias, Regelink, Josien C., Dompeling, Ellen C., Lindström, Vesa, Juliusson, Gunnar, Widmer, Anouk, Goede, Jeroen, Goldschmidt, Neta, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Ritgen, Matthias, Brüggemann, Monika, Tausch, Eugen, Spaargaren, Marcel, Eldering, Eric, Stilgenbauer, Stephan, Niemann, Carsten U., Hallek, Michael, Eichhorst, Barbara, Kreuzer, Karl-Anton, and Kater, Arnon P.

Published
2023
Full Text
View/download PDF

21. Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy

Author

Baech, Joachim, Severinsen, Marianne Tang, Øvlisen, Andreas K., Frederiksen, Henrik, Vestergaard, Peter, Torp-Pedersen, Christian, Jørgensen, Judit, Clausen, Michael Roost, Poulsen, Christian B., Brown, Peter, Gang, Anne Ortved, Pedersen, Robert Schou, Ekström Smedby, Karin, Eloranta, Sandra, Jakobsen, Lasse Hjort, and El-Galaly, Tarec Christoffer

Published
2022
Full Text
View/download PDF

22. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

Author

Kater, Arnon P, Levin, Mark-David, Dubois, Julie, Kersting, Sabina, Enggaard, Lisbeth, Veldhuis, Gerrit J, Mous, Rogier, Mellink, Clemens H M, van der Kevie-Kersemaekers, Anne-Marie F, Dobber, Johan A, Poulsen, Christian B, Frederiksen, Henrik, Janssens, Ann, Schjødt, Ida, Dompeling, Ellen C, Ranti, Juha, Brieghel, Christian, Mattsson, Mattias, Bellido, Mar, Tran, Hoa T T, Nasserinejad, Kazem, and Niemann, Carsten U

Published
2022
Full Text
View/download PDF

23. A Real‐World Data‐Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B‐Cell Lymphoma Patients.

Author

Jelicic, Jelena, Juul‐Jensen, Karen, Bukumiric, Zoran, Runason Simonsen, Mikkel, Roost Clausen, Michael, Ludvigsen Al‐Mashhadi, Ahmed, Schou Pedersen, Robert, Bjørn Poulsen, Christian, Ortved Gang, Anne, Brown, Peter, El‐Galaly, Tarec Christoffer, and Stauffer Larsen, Thomas

Subjects
B cell lymphoma, PROGNOSTIC models, OVERALL survival, DIFFUSE large B-cell lymphomas, CLINICAL trials
Abstract

Objectives: Recent front‐line clinical trials used the International Prognostic Index (IPI) to identify trial‐eligible patients with newly diagnosed diffuse large B‐cell lymphoma (DLBCL). However, many IPI‐like variants with improved accuracy have been developed over the years for rituximab‐treated patients. Methods: We assessed the impact of International Prognostic Indices on patient enrolment in clinical trials, aiming to exclude low‐risk IPI patients based on POLARIX/EPCORE DLBCL‐2 trial criteria. Results: We identified 2877 patients in the Danish Lymphoma Registry who would have been eligible for the POLARIX trial if patients with IPI 0–1 scores were included. IPI and NCCN‐IPI assigned 33.3% and 11.9% of patients to the low‐risk group, respectively. Shorter 5‐year overall survival (91.4% vs. 97.5%), higher relapse rate (9.9% vs. 4.4%), and more deaths (16.1% vs. 4.4%) occurred in the low‐risk IPI group compared with low‐risk NCCN‐IPI group. Analyzed models failed to identify true high‐risk patients with poor prognosis. Similar results were found in the confirmatory cohort developed based on EPCORE DLBCL‐2 trial eligibility criteria. Conclusion: True low‐risk patients are more optimal identified by NCCN‐IPI and should be excluded from front‐line clinical trials due to their excellent prognosis. However, additional high‐risk factors besides clinical prognostic models need to be considered when selecting trial‐eligible patients. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

24. The impact of trial inclusion criteria on outcomes in DLBCL patients treated with R-CHOP in the first line: a Danish nationwide study.

Author

Simonsen, Mikkel Runason, Haunstrup, Laura Mors, Severinsen, Freja Tang, Jensen, Rasmus Kuhr, Brown, Peter de Nully, Maurer, Matthew J., Khurana, Arushi, Jensen, Paw, Jørgensen, Judit Mészáros, Stauffer Larsen, Thomas, Clausen, Michael Roost, Poulsen, Christian Bjørn, Dessau-Arp, Andriette, El-Galaly, Tarec Christoffer, and Jakobsen, Lasse Hjort

Subjects
DIFFUSE large B-cell lymphomas, DRUG efficacy, OVERALL survival, ANTINEOPLASTIC combined chemotherapy protocols, CLINICAL trials
Abstract

Up to 50% of diffuse large B-cell lymphoma (DLBCL) patients are ineligible for participation in clinical trials. Ineligible patients have inferior outcomes, but less is known about the impact of commonly used organ-function-based inclusion criteria on drug efficacy estimates. Data on DLBCL patients treated with CHOP+/-rituximab were retrieved from the Danish Lymphoma Registry. Trial inclusion criteria were extracted from four international DLBCL trials (REMoDL-B, GOYA, POLARIX, and HOVON-84). Differences in overall survival (OS) and 5-year restricted mean survival differences (5 y-RMSDs) between trial eligible and ineligible patients were computed. The effectiveness of adding rituximab to CHOP was quantified by the 5 y-RMSD between CHOP and R-CHOP-treated patients and the impact of individual trial criteria on estimated effectiveness was quantified by Shapley-values. In total, 4,083 R-CHOP-treated and 890 CHOP-treated DLBCL patients were included. Across the trials, 18.6-29.3% of the included R-CHOP-treated patients were deemed ineligible for trial based on organ function and performance status alone. Ineligible patients had significantly worse survival, with adjusted absolute differences in 5-year OS of 9-15%. The impact of individual criteria on the estimated effectiveness of adding rituximab to CHOP was small (Shapley-value range, −2.74-0.31). Using a smaller set of criteria derived from a data-driven approach, the number of eligible patients increased by 16-38% and the 5 y-RMSD increased by 0.7-3.1 months. In conclusion, OS among trial ineligible DLBCL patients is inferior as expected, but relaxing trial criteria would have increased the number of trial participants without making major changes in estimated efficacy for a hypothetical CHOP versus R-CHOP trial. This does not necessarily imply that trial findings based on selected patients are unreliable, as the estimated effectiveness of adding rituximab to CHOP was only slightly affected by omitting selected inclusion criteria. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Identification of an algal xylan synthase indicates that there is functional orthology between algal and plant cell wall biosynthesis

Author

Jensen, Jacob Krüger, Busse‐Wicher, Marta, Poulsen, Christian Peter, Fangel, Jonatan Ulrik, Smith, Peter James, Yang, Jeong‐Yeh, Peña, Maria‐Jesus, Dinesen, Malene Hessellund, Martens, Helle Juel, Melkonian, Michael, Wong, Gane Ka‐Shu, Moremen, Kelley W, Wilkerson, Curtis Gene, Scheller, Henrik Vibe, Dupree, Paul, Ulvskov, Peter, Urbanowicz, Breeanna Rae, and Harholt, Jesper

Subjects
Plant Biology, Biological Sciences, Amino Acid Motifs, Biosynthetic Pathways, Cell Wall, Charophyceae, Evolution, Molecular, HEK293 Cells, Humans, Pentosyltransferases, Phylogeny, Plant Cells, biosynthesis, cell wall, evolution, IRX10, Klebsormidium flaccidum, Klebsormidium nitens, xylan, XYS1, Agricultural and Veterinary Sciences, Plant Biology & Botany, Plant biology, Climate change impacts and adaptation, Ecological applications
Abstract

Insights into the evolution of plant cell walls have important implications for comprehending these diverse and abundant biological structures. In order to understand the evolving structure-function relationships of the plant cell wall, it is imperative to trace the origin of its different components. The present study is focused on plant 1,4-β-xylan, tracing its evolutionary origin by genome and transcriptome mining followed by phylogenetic analysis, utilizing a large selection of plants and algae. It substantiates the findings by heterologous expression and biochemical characterization of a charophyte alga xylan synthase. Of the 12 known gene classes involved in 1,4-β-xylan formation, XYS1/IRX10 in plants, IRX7, IRX8, IRX9, IRX14 and GUX occurred for the first time in charophyte algae. An XYS1/IRX10 ortholog from Klebsormidium flaccidum, designated K. flaccidumXYLAN SYNTHASE-1 (KfXYS1), possesses 1,4-β-xylan synthase activity, and 1,4-β-xylan occurs in the K. flaccidum cell wall. These data suggest that plant 1,4-β-xylan originated in charophytes and shed light on the origin of one of the key cell wall innovations to occur in charophyte algae, facilitating terrestrialization and emergence of polysaccharide-based plant cell walls.

Published
2018

26. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

Author

Salmanton-García, Jon, primary, Marchesi, Francesco, additional, Farina, Francesca, additional, Weinbergerová, Barbora, additional, Itri, Federico, additional, Dávila-Valls, Julio, additional, Martín-Pérez, Sonia, additional, Glenthøj, Andreas, additional, Hersby, Ditte Stampe, additional, Gomes Da Silva, Maria, additional, Nunes Rodrigues, Raquel, additional, López-García, Alberto, additional, Córdoba, Raúl, additional, Bilgin, Yavuz M., additional, Falces-Romero, Iker, additional, El-Ashwah, Shaimaa, additional, Emarah, Ziad, additional, Besson, Caroline, additional, Kohn, Milena, additional, Van Doesum, Jaap, additional, Ammatuna, Emanuele, additional, Marchetti, Monia, additional, Labrador, Jorge, additional, Zambrotta, Giovanni Paolo Maria, additional, Verga, Luisa, additional, Jaksic, Ozren, additional, Nucci, Marcio, additional, Piukovics, Klára, additional, Cabirta-Touzón, Alba, additional, Jiménez, Moraima, additional, Arellano, Elena, additional, Espigado, Ildefonso, additional, Blennow, Ola, additional, Nordlander, Anna, additional, Meers, Stef, additional, Vian Praet, Jens, additional, Aiello, Tommaso Francesco, additional, Garcia-Vidal, Carolina, additional, Fracchiolla, Nicola S., additional, Sciumè, Mariarita, additional, Seval, Guldane Cengiz, additional, Žák, Pavel, additional, Buquicchio, Caterina, additional, Tascini, Carlo, additional, Gräfe, Stefanie K., additional, Schönlein, Martin, additional, Adžić-VUKIČEVIĆ, Tatjana, additional, Bonuomo, Valentina, additional, Cattaneo, Chiara, additional, Nizamuddin, Summiya, additional, Čerňan, Martin, additional, Plantefeve, Gaëtan, additional, Prin, Romane, additional, Szotkovski, Tomas, additional, Collins, Graham P., additional, Dargenio, Michelina, additional, Petzer, Verena, additional, Wolf, Dominik, additional, Čolović, Natasha, additional, Prezioso, Lucia, additional, Valković, Toni, additional, Passamonti, Francesco, additional, Méndez, Gustavo-Adolfo, additional, Sili, Uluhan, additional, Vena, Antonio, additional, Bavastro, Martina, additional, Limongelli, Alessandro, additional, Duarte, Rafael F., additional, Ledoux, Marie-Pierre, additional, Cvetanoski, Milche, additional, Stojanoski, Zlate, additional, Machado, Marina, additional, Batinić, Josip, additional, Magliano, Gabriele, additional, Biernat, Monika M., additional, Pantić, Nikola, additional, Poulsen, Christian Bjørn, additional, Cuccaro, Annarosa, additional, Del Principe, Maria Ilaria, additional, Kulasekararaj, Austin, additional, Ormazabal-Vélez, Irati, additional, Busca, Alessandro, additional, Demirkan, Fatih, additional, Ijaz, Marriyam, additional, Klimko, Nikolai, additional, Stoma, Igor, additional, Khostelidi, Sofya, additional, Fernández, Noemí, additional, Omrani, Ali S., additional, Bergantim, Rui, additional, De Jonge, Nick, additional, Fouquet, Guillemette, additional, Navrátil, Milan, additional, Abu-Zeinah, Ghaith, additional, Samarkos, Michail, additional, Maertens, Johan, additional, De Ramón, Cristina, additional, Guidetti, Anna, additional, Magyari, Ferenc, additional, González-López, Tomás José, additional, Lahmer, Tobias, additional, Finizio, Olimpia, additional, Ali, Natasha, additional, Pinczés, László Imre, additional, Lavilla-Rubira, Esperanza, additional, Romano, Alessandra, additional, Merelli, Maria, additional, Delia, Mario, additional, Calbacho, Maria, additional, Meletiadis, Joseph, additional, Antić, Darko, additional, Hernández-Rivas, José-Ángel, additional, Marques De Almeida, Joyce, additional, Al-Khabori, Murtadha, additional, Hoenigl, Martin, additional, Tisi, Maria Chiara, additional, Khanna, Nina, additional, Barać, Aleksandra, additional, Eisa, Noha, additional, Di Blasi, Roberta, additional, Liévin, Raphaël, additional, Miranda-Castillo, Carolina, additional, Bahr, Nathan C., additional, Lamure, Sylvain, additional, Papa, Mario Virgilio, additional, Yahya, Ayel, additional, Aujayeb, Avinash, additional, Novák, Jan, additional, Erben, Nurettin, additional, Fernández-Galán, María, additional, Ribera-Santa Susana, José-María, additional, Rinaldi, Ikhwan, additional, Fazzi, Rita, additional, Piedimonte, Monica, additional, Duléry, Rémy, additional, Gonzaga, Yung, additional, Soto-Silva, Andrés, additional, Sapienza, Giuseppe, additional, Serris, Alexandra, additional, Drgoňa, Ľuboš, additional, Groh, Ana, additional, Serrano, Laura, additional, Gavriilaki, Eleni, additional, Tragiannidis, Athanasios, additional, Prattes, Juergen, additional, Coppola, Nicola, additional, Otašević, Vladimir, additional, Mladenović, Miloš, additional, Mitrović, Mirjana, additional, Mišković, Bojana, additional, Jindra, Pavel, additional, Zompi, Sofia, additional, Sacchi, Maria Vittoria, additional, Krekeler, Carolin, additional, Shumilov, Evgenii, additional, Infante, Maria Stefania, additional, García-Bordallo, Daniel, additional, Çolak, Gökçe Melis, additional, Cingolani, Antonella, additional, Mayer, Jiří, additional, Criscuolo, Marianna, additional, Nygaard, Marietta, additional, Hanáková, Michaela, additional, Fianchi, Luana, additional, Ráčil, Zdeněk, additional, Giordano, Antonio, additional, Quattrone, Martina, additional, Bonanni, Matteo, additional, Koehler, Philipp, additional, Rahimli, Laman, additional, Cornely, Oliver A., additional, Pagano, Livio, additional, Martín-Vallejo, Francisco Javier, additional, Zdziarski, Przemyslaw, additional, Zarrinfer, Hossein, additional, Wittig, Jana, additional, Win, Sein, additional, Wai-Man, Vivien, additional, Víšek, Benjamín, additional, Vinh, Donald C., additional, Vehreschild, Maria, additional, Varricchio, Gina, additional, Tsirigotis, Panagiotis, additional, Torres-Tienza, Ana, additional, Tanase, Alina Daniela, additional, Tafuri, Agostino, additional, Stamouli, Maria, additional, Sramek, Jiří, additional, Soussain, Carole, additional, Shirinova, Ayten, additional, Schubert, Jörg, additional, Schalk, Enrico, additional, Salehi, Mohammad Reza, additional, Saleh, Modar, additional, Rosati, Giorgio, additional, Roldán, Elisa, additional, Reizine, Florian, additional, Rêgo, Mayara, additional, Regalado-Artamendi, Isabel, additional, Popova, Marina, additional, Pinto, Fernando, additional, Philippe, Laure, additional, Orth, Hans Martin, additional, Ommen, Hans-Beier, additional, Obr, Aleš, additional, Núñez-Martín-Buitrago, Lucía, additional, Noël, Nicolas, additional, Neuhann, Julia, additional, Nadali, Gianpaolo, additional, Nacov, Julia A., additional, Munhoz Alburquerque, Ana M., additional, Mitra, Maria Enza, additional, Mikulska, Malgorzata, additional, Mellinghoff, Sibylle, additional, Mechtel, Ben, additional, Martín-González, Juan-Alberto, additional, Malak, Sandra, additional, Loureiro-Amigo, Jorge, additional, Lorenzo De La Peña, Lisset, additional, Liberti, Giulia, additional, Landau, Marianne, additional, Lacej, Ira, additional, Kolditz, Martin, additional, Kho, Chi Shan, additional, Khedr, Reham Abdelaziz, additional, Karthaus, Meinolf, additional, Karlsson, Linda Katharina, additional, Jiménez-Lorenzo, María-Josefa, additional, Izuzquiza, Macarena, additional, Hoell-Neugebauer, Baerbel, additional, Herbrecht, Raoul, additional, Heath, Christopher H., additional, Guolo, Fabio, additional, Grothe, Jan, additional, Gerasymchuk, Sergey, additional, García-Sanz, Ramón, additional, García-Poutón, Nicole, additional, Funke, Vaneuza Araújo Moreira, additional, Fung, Monica, additional, Flasshove, Charlotte, additional, Essame, Jenna, additional, Egger, Matthias, additional, Drenou, Bernard, additional, Dragonetti, Giulia, additional, Desole, Maximilian, additional, Della Pepa, Roberta, additional, Deau Fischer, Bénédicte, additional, De Kort, Elizabeth, additional, De Cabo, Erik, additional, Danion, François, additional, Daguindau, Etienne, additional, Cushion, Tania, additional, Cremer, Louise, additional, Cordini, Gregorio, additional, Ciceri, Fabio, additional, Chowdhury, Fazle Rabbi, additional, Chelysheva, Ekaterina, additional, Chauchet, Adrien, additional, Chai, Louis Yi Ann, additional, Ceesay, M. Mansour, additional, Busch, Elena, additional, Brehon, Mathias, additional, Borducchi, Davimar M.M., additional, Booth, Stephen, additional, Bologna, Serge, additional, Berg Venemyr, Caroline, additional, Bailén-Almorox, Rebeca, additional, Antoniadou, Anastasia, additional, Anastasopoulou, Amalia N., additional, and Altuntaş, Fevzi, additional

Published
2024
Full Text
View/download PDF

28. Emergence and fixation of SARS‐CoV‐2 minority variants in a chronically infected patient receiving therapy in Denmark.

Author

Fonager, Jannik, Nytofte, Nikolaj Julian Skrøder, Schouw, Christian Højte, Poulsen, Christian B., Wiese, Lothar, Fomsgaard, Anders, Bennedbæk, Marc, Rasmussen, Morten, and Nielsen, Xiaohui Chen

Subjects
SARS-CoV-2 Omicron variant, IMMUNOCOMPROMISED patients, REMDESIVIR, IMMUNOGLOBULINS, GENOMES
Abstract

SARS‐CoV‐2 variants of concern (VOC), such as Delta and Omicron have harbored mutations, which increased viral infectivity or ability to evade neutralizing antibodies. Immunocompromised patients might be a source of some of these emerging variants. In this study, we sequenced 17 consecutive samples from an immunocompromised patient with a long‐term SARS‐CoV‐2 infection with the pre‐VOC era lineage B.1.177.35. We here describe the emergence of 73 nonsynonymous minority variants in this patient and show that 10 of these mutations became dominant in the viral population during the treatment period. Four of these were seen throughout the infection period and had a very low global prevalence, although three of them were also observed later in the Alpha, Delta, and Omicron lineages. We also found that two adjacent nsp12 variants (M785I and S786P) belonged to different quasi‐species and competed during the early stages of infection and remdesivir administration. This emphasizes the importance of ongoing genome surveillance of SARS‐CoV‐2 among immunocpromised patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

Author

Gilead Sciences, Projekt DEAL, Espigado, Ildefonso [0000-0002-4043-6613], Lahmer, Tobias, Salmanton-García, Jon, Marchesi, Francesco, El-Ashwah, Shaimaa, Nucci, Marcio, Besson, Caroline, Itri, Federico, Jaksic, Ozren, Čolović, Natasha, Weinbergerová, Barbora, Seval, Guldane Cengiz, Adžić-Vukičević, Tatjana, Szotkowski, Tomáš, Sili, Uluhan, Dargenio, Michelina, van Praet, Jens, van Doesum, Jaap, Schönlein, Martin, Ráčil, Zdeněk, Žák, Pavel, Poulsen, Christian Bjørn, Magliano, Gabriele, Jiménez, Moraima, Bonuomo, Valentina, Piukovics, Klára, Dragonetti, Giulia, Demirkan, Fatih, Blennow, Ola, Valković, Toni, Gomes Da Silva, Maria, Maertens, Johan, Glenthøj, Andreas, Fernández, Noemí, Bergantim, Rui, Verga, Luisa, Petzer, Verena, Omrani, Ali S., Méndez, Gustavo-Adolfo, Machado, Marina, Ledoux, Marie-Pierre, Bailén, Rebeca, Duarte, Rafael F., Del Principe, Maria Ilaria, Farina, Francesca, Martín-Pérez, Sonia, Dávila-Valls, Julio, Marchetti, Monia, Bilgin, Yavuz M., Fracchiolla, Nicola S., Cattaneo, Chiara, Espigado, Ildefonso, Cordoba, Raul, Collins, Graham P., Labrador, Jorge, Falces-Romero, Iker, Prezioso, Lucia, Meers, Stef, Passamonti, Francesco, Buquicchio, Caterina, López-García, Alberto, Kulasekararaj, Austin, Ormazabal-Vélez, Irati, Cuccaro, Annarosa, Garcia-Vidal, Carolina, Busca, Alessandro, Navrátil, Milan, de Jonge, Nick, Biernat, Monika M., Guidetti, Anna, Abu-Zeinah, Ghaith, Samarkos, Michail, Anastasopoulou, Amalia, de Ramón, Cristina, González-López, Tomás José, Hoenigl, Martin, Finizio, Olimpia, Pinczés, László Imre, Ali, Natasha, Vena, Antonio, Tascini, Carlo, Stojanoski, Zlate, Merelli, Maria, Emarah, Ziad, Kohn, Milena, Barać, Aleksandra, Mladenović, Miloš, Mišković, Bojana, Ilhan, Osman, Çolak, Gökçe Melis, Čerňan, Martin, Gräfe, Stefanie K., Ammatuna, Emanuele, Hanakova, Michaela, Víšek, Benjamín, Cabirta, Alba, Nordlander, Anna, Nunes Rodrigues, Raquel, Hersby, Ditte Stampe, Zambrotta, Giovanni Paolo Maria, Wolf, Dominik, Núñez-Martín-Buitrago, Lucía, Arellano, Elena, Aiello, Tommaso Francesco, García-Sanz, Ramón, Prattes, Juergen, Egger, Matthias, Limongelli, Alessandro, Bavastro, Martina, Cvetanoski, Milche, Dibos, Miriam, Rasch, Sebastian, Rahimli, Laman, Cornely, Oliver A., Pagano, Livio, Gilead Sciences, Projekt DEAL, Espigado, Ildefonso [0000-0002-4043-6613], Lahmer, Tobias, Salmanton-García, Jon, Marchesi, Francesco, El-Ashwah, Shaimaa, Nucci, Marcio, Besson, Caroline, Itri, Federico, Jaksic, Ozren, Čolović, Natasha, Weinbergerová, Barbora, Seval, Guldane Cengiz, Adžić-Vukičević, Tatjana, Szotkowski, Tomáš, Sili, Uluhan, Dargenio, Michelina, van Praet, Jens, van Doesum, Jaap, Schönlein, Martin, Ráčil, Zdeněk, Žák, Pavel, Poulsen, Christian Bjørn, Magliano, Gabriele, Jiménez, Moraima, Bonuomo, Valentina, Piukovics, Klára, Dragonetti, Giulia, Demirkan, Fatih, Blennow, Ola, Valković, Toni, Gomes Da Silva, Maria, Maertens, Johan, Glenthøj, Andreas, Fernández, Noemí, Bergantim, Rui, Verga, Luisa, Petzer, Verena, Omrani, Ali S., Méndez, Gustavo-Adolfo, Machado, Marina, Ledoux, Marie-Pierre, Bailén, Rebeca, Duarte, Rafael F., Del Principe, Maria Ilaria, Farina, Francesca, Martín-Pérez, Sonia, Dávila-Valls, Julio, Marchetti, Monia, Bilgin, Yavuz M., Fracchiolla, Nicola S., Cattaneo, Chiara, Espigado, Ildefonso, Cordoba, Raul, Collins, Graham P., Labrador, Jorge, Falces-Romero, Iker, Prezioso, Lucia, Meers, Stef, Passamonti, Francesco, Buquicchio, Caterina, López-García, Alberto, Kulasekararaj, Austin, Ormazabal-Vélez, Irati, Cuccaro, Annarosa, Garcia-Vidal, Carolina, Busca, Alessandro, Navrátil, Milan, de Jonge, Nick, Biernat, Monika M., Guidetti, Anna, Abu-Zeinah, Ghaith, Samarkos, Michail, Anastasopoulou, Amalia, de Ramón, Cristina, González-López, Tomás José, Hoenigl, Martin, Finizio, Olimpia, Pinczés, László Imre, Ali, Natasha, Vena, Antonio, Tascini, Carlo, Stojanoski, Zlate, Merelli, Maria, Emarah, Ziad, Kohn, Milena, Barać, Aleksandra, Mladenović, Miloš, Mišković, Bojana, Ilhan, Osman, Çolak, Gökçe Melis, Čerňan, Martin, Gräfe, Stefanie K., Ammatuna, Emanuele, Hanakova, Michaela, Víšek, Benjamín, Cabirta, Alba, Nordlander, Anna, Nunes Rodrigues, Raquel, Hersby, Ditte Stampe, Zambrotta, Giovanni Paolo Maria, Wolf, Dominik, Núñez-Martín-Buitrago, Lucía, Arellano, Elena, Aiello, Tommaso Francesco, García-Sanz, Ramón, Prattes, Juergen, Egger, Matthias, Limongelli, Alessandro, Bavastro, Martina, Cvetanoski, Milche, Dibos, Miriam, Rasch, Sebastian, Rahimli, Laman, Cornely, Oliver A., and Pagano, Livio

Abstract

The risk for a severe coronavirus disease 2019 (COVID-19) with need for an intensive care unit (ICU) admission in a non-immunocompromised vaccinated population dropped from 5% at the beginning of the pandemic to at least 0.2% and is still decreasing since the omicron strain dominates the COVID-19 pandemic [1]. Beyond the risk factors identified for a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection like male sex, older age, and comorbidities such as cardiovascular disease, lung disease or obesity, patients with a history of malignancy, specifically patients with haematological malignancy, are prone to develop a complicated SARS-CoV-2 infection with need for ICU which is still associated with poorer clinical outcome [2,3,4,5,6,7,8,9,10,11,12,13,14,15]. The circumstances of a widely heterogenous population with regards to the type of haematological malignancy, extent of disease, haematological malignancy treatment history, [16,17,18] and baseline performance status are even more challenging in the environment of an ICU [19]. Although, data referring to critically ill COVID-19 patients regarding treatment strategies and outcome are widely available, data referring to critically ill patients with haematological malignancy are scarce and underreported [20]. The aim of this study is to analyze the epidemiology, risk factors and outcome of patients with haematological malignancy with need for an ICU setting using the data from the large-scale EPICOVIDEHA registry of the European Hematology Association—Scientific Working Group Infectious in Hematology (EHA-SWG) [21].

Published
2024

31. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022

Author

Arellano-Orden, Elena [0000-0003-0581-8947], Salmanton-García, Jon, Marchesi, Francesco, Farina, Francesca, Weinbergerová, Barbora, Itri, Federico, Dávila-Valls, Julio, Martín-Pérez, Sonia, Glenthøj, Andreas, Hersby, Ditte Stampe, Gomes da Silva, Maria, Nunes Rodrigues, Raquel, López-García, Alberto, Córdoba, Raúl, Bilgin, Yavuz M., Falces-Romero, Iker, El-Ashwah, Shaimaa, Emarah, Ziad, Besson, Caroline, Kohn, Milena, Van Doesum, Jaap, Ammatuna, Emanuele, Marchetti, Monia, Labrador, Jorge, Zambrotta, Giovanni Paolo Maria, Verga, Luisa, Jaksic, Ozren, Nucci, Marcio, Piukovics, Klára, Cabirta-Touzón, Alba, Jiménez, Moraima, Arellano-Orden, Elena, Espigado, Ildefonso, Blennow, Ola, Nordlander, Anna, Meers, Stef, van Praet, Jens, Aiello, Tommaso Francesco, Garcia-Vidal, Carolina, Fracchiolla, Nicola, Sciumè, Mariarita, Seval, Guldane Cengiz, Žák, Pavel, Buquicchio, Caterina, Tascini, Carlo, Gräfe, Stefanie K., Schönlein, Martin, Adžić-Vukičević, Tatjana, Bonuomo, Valentina, Cattaneo, Chiara, Nizamuddin, Summiya, Čerňan, Martin, Plantefeve, Gaëtan, Prin, Romane, Szotkovski, Tomas, Collins, Graham P., Dargenio, Michelina, Petzer, Verena, Wolf, Dominik, Čolović, Natasha, Prezioso, Lucia, Valković, Toni, Passamonti, Francesco, Méndez, Gustavo-Adolfo, Sili, Uluhan, Vena, Antonio, Bavastro, Martina, Limongelli, Alessandro, Duarte, Rafael F., Ledoux, Marie-Pierre, Cvetanoski, Milche, Stojanoski, Zlate, Machado, Marina, Batinić, Josip, Magliano, Gabriele, Biernat, Monika M., Pantić, Nikola, Poulsen, Christian Bjørn, Cuccaro, Annarosa, Del Principe, Maria Ilaria, Kulasekararaj, Austin, Ormazabal-Vélez, Irati, Busca, Alessandro, Demirkan, Fatih, Ijaz, Marriyam, Klimko, Nikolai, Stoma, Igor, Khostelidi, Sofya, Fernández, Noemí, Omrani, Ali S, Bergantim, Rui, De Jonge, Nick, Fouquet, Guillemette, Navrátil, Milan, Abu-Zeinah, Ghaith, Samarkos, Michail, Maertens, Johan, De Ramón, Cristina, Guidetti, Anna, Magyari, Ferenc, González-López, Tomás José, Lahmer, Tobias, Finizio, Olimpia, Ali, Natasha, Pinczés, László Imre, Lavilla-Rubira, Esperanza, Romano, Alessandra, Merelli, Maria, Delia, Mario, Calbacho, Maria, Meletiadis, Joseph, Antić, Darko, Hernández-Rivas, José-Ángel, Marques de Almeida, Joyce, Al-Khabori, Murtadha, Hoenigl, Martin, Tisi, Maria Chiara, Khanna, Nina, Barać, Aleksandra, Eisa, Noha, Di Blasi, Roberta, Liévin, Raphaël, Miranda-Castillo, Carolina, Bahr, Nathan C., Lamure, Sylvain, Papa, Mario Virgilio, Yahya, Ayel, Aujayeb, Avinash, Novák, Jan, Erben, Nurettin, Fernández-Galán, María, Ribera-Santa Susana, José-María, Rinaldi, Ikhwan, Fazzi, Rita, Piedimonte, Monica, Duléry, Rémy, Gonzaga, Yung, Soto-Silva, Andrés, Sapienza, Giuseppe, Serris, Alexandra, Drgoňa, Ľuboš, Groh, Ana, Serrano, Laura, Gavriilaki, Eleni, Tragiannidis, Athanasios, Prattes, Juergen, Coppola, Nicola, Otašević, Vladimir, Mladenović, Miloš, Mitrović, Mirjana, Mišković, Bojana, Jindra, Pavel, Zompi, Sofia, Sacchi, Maria Vittoria, Krekeler, Carolin, Infante, Maria Stefania, García-Bordallo, Daniel, Çolak, Gökçe Melis, Mayer, Jiří, Nygaard, Marietta, Hanáková, Michaela, Ráčil, Zdeněk, Bonanni, Matteo, Koehler, Philipp, Rahimli, Laman, Cornely, Oliver A., Pagano, Livio, Arellano-Orden, Elena [0000-0003-0581-8947], Salmanton-García, Jon, Marchesi, Francesco, Farina, Francesca, Weinbergerová, Barbora, Itri, Federico, Dávila-Valls, Julio, Martín-Pérez, Sonia, Glenthøj, Andreas, Hersby, Ditte Stampe, Gomes da Silva, Maria, Nunes Rodrigues, Raquel, López-García, Alberto, Córdoba, Raúl, Bilgin, Yavuz M., Falces-Romero, Iker, El-Ashwah, Shaimaa, Emarah, Ziad, Besson, Caroline, Kohn, Milena, Van Doesum, Jaap, Ammatuna, Emanuele, Marchetti, Monia, Labrador, Jorge, Zambrotta, Giovanni Paolo Maria, Verga, Luisa, Jaksic, Ozren, Nucci, Marcio, Piukovics, Klára, Cabirta-Touzón, Alba, Jiménez, Moraima, Arellano-Orden, Elena, Espigado, Ildefonso, Blennow, Ola, Nordlander, Anna, Meers, Stef, van Praet, Jens, Aiello, Tommaso Francesco, Garcia-Vidal, Carolina, Fracchiolla, Nicola, Sciumè, Mariarita, Seval, Guldane Cengiz, Žák, Pavel, Buquicchio, Caterina, Tascini, Carlo, Gräfe, Stefanie K., Schönlein, Martin, Adžić-Vukičević, Tatjana, Bonuomo, Valentina, Cattaneo, Chiara, Nizamuddin, Summiya, Čerňan, Martin, Plantefeve, Gaëtan, Prin, Romane, Szotkovski, Tomas, Collins, Graham P., Dargenio, Michelina, Petzer, Verena, Wolf, Dominik, Čolović, Natasha, Prezioso, Lucia, Valković, Toni, Passamonti, Francesco, Méndez, Gustavo-Adolfo, Sili, Uluhan, Vena, Antonio, Bavastro, Martina, Limongelli, Alessandro, Duarte, Rafael F., Ledoux, Marie-Pierre, Cvetanoski, Milche, Stojanoski, Zlate, Machado, Marina, Batinić, Josip, Magliano, Gabriele, Biernat, Monika M., Pantić, Nikola, Poulsen, Christian Bjørn, Cuccaro, Annarosa, Del Principe, Maria Ilaria, Kulasekararaj, Austin, Ormazabal-Vélez, Irati, Busca, Alessandro, Demirkan, Fatih, Ijaz, Marriyam, Klimko, Nikolai, Stoma, Igor, Khostelidi, Sofya, Fernández, Noemí, Omrani, Ali S, Bergantim, Rui, De Jonge, Nick, Fouquet, Guillemette, Navrátil, Milan, Abu-Zeinah, Ghaith, Samarkos, Michail, Maertens, Johan, De Ramón, Cristina, Guidetti, Anna, Magyari, Ferenc, González-López, Tomás José, Lahmer, Tobias, Finizio, Olimpia, Ali, Natasha, Pinczés, László Imre, Lavilla-Rubira, Esperanza, Romano, Alessandra, Merelli, Maria, Delia, Mario, Calbacho, Maria, Meletiadis, Joseph, Antić, Darko, Hernández-Rivas, José-Ángel, Marques de Almeida, Joyce, Al-Khabori, Murtadha, Hoenigl, Martin, Tisi, Maria Chiara, Khanna, Nina, Barać, Aleksandra, Eisa, Noha, Di Blasi, Roberta, Liévin, Raphaël, Miranda-Castillo, Carolina, Bahr, Nathan C., Lamure, Sylvain, Papa, Mario Virgilio, Yahya, Ayel, Aujayeb, Avinash, Novák, Jan, Erben, Nurettin, Fernández-Galán, María, Ribera-Santa Susana, José-María, Rinaldi, Ikhwan, Fazzi, Rita, Piedimonte, Monica, Duléry, Rémy, Gonzaga, Yung, Soto-Silva, Andrés, Sapienza, Giuseppe, Serris, Alexandra, Drgoňa, Ľuboš, Groh, Ana, Serrano, Laura, Gavriilaki, Eleni, Tragiannidis, Athanasios, Prattes, Juergen, Coppola, Nicola, Otašević, Vladimir, Mladenović, Miloš, Mitrović, Mirjana, Mišković, Bojana, Jindra, Pavel, Zompi, Sofia, Sacchi, Maria Vittoria, Krekeler, Carolin, Infante, Maria Stefania, García-Bordallo, Daniel, Çolak, Gökçe Melis, Mayer, Jiří, Nygaard, Marietta, Hanáková, Michaela, Ráčil, Zdeněk, Bonanni, Matteo, Koehler, Philipp, Rahimli, Laman, Cornely, Oliver A., and Pagano, Livio

Abstract

The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals, and monoclonal antibodies have been effective for the general population, their benefits for these patients may not be as pronounced.

Published
2024

32. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry

Author

Optics COMMIT, Gilead Sciences, Espigado, Ildefonso [0000-0002-4043-6613], Musto, Pellegrino, Salmanton-García, Jon, Sgherza, Nicola, Bergantim, Rui, Farina, Francesca, Glenthøj, Andreas, Cengiz Seval, Guldane, Weinbergerová, Barbora, Bonuomo, Valentina, Bilgin, Yavuz M., van Doesum, Jaap, Jaksic, Ozren, Víšek, Benjamín, Falces-Romero, Iker, Marchetti, Monia, Dávila-Valls, Julio, Martín-Pérez, Sonia, Nucci, Marcio, López-García, Alberto, Itri, Federico, Buquicchio, Caterina, Verga, Luisa, Piukovics, Klára, Navrátil, Milan, Collins, Graham P., Jiménez, Moraima, Fracchiolla, Nicola S., Labrador, Jorge, Prezioso, Lucia, Rossi, Elena, Čolović, Natasha, Meers, Stef, Kulasekararaj, Austin, Cuccaro, Annarosa, Blennow, Ola, Valković, Toni, Sili, Uluhan, Ledoux, Marie-Pierre, Batinić, Josip, Passamonti, Francesco, Machado, Marina, Duarte, Rafael F., Poulsen, Christian Bjørn, Méndez, Gustavo-Adolfo, Espigado, Ildefonso, Demirkan, Fatih, Čerňan, Martin, Cattaneo, Chiara, Petzer, Verena, Magliano, Gabriele, Garcia-Vidal, Carolina, El-Ashwah, Shaimaa, Gomes-Da-Silva, Maria, Vena, Antonio, Ormazabal-Vélez, Irati, van Praet, Jens, Dargenio, Michelina, De-Ramón, Cristina, Del Principe, Maria Ilaria, Marques-De-Almeida, Joyce, Wolf, Dominik, Szotkowski, Tomáš, Obr, Aleš, Çolak, Gökçe Melis, Nordlander, Anna, Izuzquiza, Macarena, Cabirta, Alba, Zambrotta, Giovanni Paolo Maria, Cordoba, Raul, Žák, Pavel, Ammatuna, Emanuele, Mayer, Jiří, Ilhan, Osman, García-Sanz, Ramón, Quattrone, Martina, Arellano, Elena, Nunes-Rodrigues, Raquel, Emarah, Ziad, Aiello, Tommaso Francesco, Hanakova, Michaela, Ráčil, Zdeněk, Bavastro, Martina, Limongelli, Alessandro, Rahimli, Laman, Marchesi, Francesco, Cornely, Oliver A., Pagano, Livio, Optics COMMIT, Gilead Sciences, Espigado, Ildefonso [0000-0002-4043-6613], Musto, Pellegrino, Salmanton-García, Jon, Sgherza, Nicola, Bergantim, Rui, Farina, Francesca, Glenthøj, Andreas, Cengiz Seval, Guldane, Weinbergerová, Barbora, Bonuomo, Valentina, Bilgin, Yavuz M., van Doesum, Jaap, Jaksic, Ozren, Víšek, Benjamín, Falces-Romero, Iker, Marchetti, Monia, Dávila-Valls, Julio, Martín-Pérez, Sonia, Nucci, Marcio, López-García, Alberto, Itri, Federico, Buquicchio, Caterina, Verga, Luisa, Piukovics, Klára, Navrátil, Milan, Collins, Graham P., Jiménez, Moraima, Fracchiolla, Nicola S., Labrador, Jorge, Prezioso, Lucia, Rossi, Elena, Čolović, Natasha, Meers, Stef, Kulasekararaj, Austin, Cuccaro, Annarosa, Blennow, Ola, Valković, Toni, Sili, Uluhan, Ledoux, Marie-Pierre, Batinić, Josip, Passamonti, Francesco, Machado, Marina, Duarte, Rafael F., Poulsen, Christian Bjørn, Méndez, Gustavo-Adolfo, Espigado, Ildefonso, Demirkan, Fatih, Čerňan, Martin, Cattaneo, Chiara, Petzer, Verena, Magliano, Gabriele, Garcia-Vidal, Carolina, El-Ashwah, Shaimaa, Gomes-Da-Silva, Maria, Vena, Antonio, Ormazabal-Vélez, Irati, van Praet, Jens, Dargenio, Michelina, De-Ramón, Cristina, Del Principe, Maria Ilaria, Marques-De-Almeida, Joyce, Wolf, Dominik, Szotkowski, Tomáš, Obr, Aleš, Çolak, Gökçe Melis, Nordlander, Anna, Izuzquiza, Macarena, Cabirta, Alba, Zambrotta, Giovanni Paolo Maria, Cordoba, Raul, Žák, Pavel, Ammatuna, Emanuele, Mayer, Jiří, Ilhan, Osman, García-Sanz, Ramón, Quattrone, Martina, Arellano, Elena, Nunes-Rodrigues, Raquel, Emarah, Ziad, Aiello, Tommaso Francesco, Hanakova, Michaela, Ráčil, Zdeněk, Bavastro, Martina, Limongelli, Alessandro, Rahimli, Laman, Marchesi, Francesco, Cornely, Oliver A., and Pagano, Livio

Abstract

Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world. Median follow-up was 52 days for the entire cohort and 83 days for survivors. Three-hundred and three patients died (24%) and COVID-19 was the primary reason for death of around 89% of them. Overall survival (OS) was significantly higher in vaccinated patients with both stable and active MM versus unvaccinated, while only a trend favoring vaccinated patients was observed in subjects with responsive MM. Vaccinated patients with at least 2 doses showed a better OS than those with one or no vaccine dose. Overall, according to pandemic waves, mortality rate decreased over time from 34% to 10%. In multivariable analysis, age, renal failure, active disease, hospital, and intensive care unit admission, were independently associated with a higher number of deaths, while a neutrophil count above 0.5 × 109 /L was found to be protective. This data suggests that MM patients remain at risk of SARS-CoV-2 infection even in the vaccination era, but their clinical outcome, in terms of OS, has progressively improved throughout the different viral phases of the pandemic.

Published
2024

33. Real-world outcomes following third or subsequent lines of therapy:A Danish population-based study on 189 patients with relapsed/refractory large B-cell lymphomas

Author

AL-Mashhadi, Ahmed Ludvigsen, Jakobsen, Lasse Hjort, Brown, Peter, Gang, Anne Ortved, Thorsteinsson, Anne Luise, Rasoul, Kaziwa, Haissman, Judith Melchior, Tøstesen, Michael Buch, Christoffersen, Mette Niemann, Jelicic, Jelena, Jørgensen, Jennifer Bøgh, Thomsen, Troels, Dessau-Arp, Andriette, Andersen, Andreas P.H., Frederiksen, Mikael, Pedersen, Per Trøllund, Clausen, Michael Roost, Jørgensen, Judit Meszaros, Poulsen, Christian Bjørn, El-Galaly, Tarec Christoffer, Larsen, Thomas Stauffer, AL-Mashhadi, Ahmed Ludvigsen, Jakobsen, Lasse Hjort, Brown, Peter, Gang, Anne Ortved, Thorsteinsson, Anne Luise, Rasoul, Kaziwa, Haissman, Judith Melchior, Tøstesen, Michael Buch, Christoffersen, Mette Niemann, Jelicic, Jelena, Jørgensen, Jennifer Bøgh, Thomsen, Troels, Dessau-Arp, Andriette, Andersen, Andreas P.H., Frederiksen, Mikael, Pedersen, Per Trøllund, Clausen, Michael Roost, Jørgensen, Judit Meszaros, Poulsen, Christian Bjørn, El-Galaly, Tarec Christoffer, and Larsen, Thomas Stauffer

Abstract

Outcome data of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) beyond the second line are scarce outside of clinical trials. Novel therapies in the R/R setting have been approved based on single-arm trials, but results need to be contextualized by real-world outcomes. Medical records from 3753 Danish adults diagnosed with DLBCL were reviewed. Patients previously treated with rituximab and anthracycline-based chemotherapy who received the third or later line (3 L+) of treatment after 1 January 2015, were included. Only 189 patients with a median age of 71 years were eligible. The median time since the last line of therapy was 6 months. Patients were treated with either best supportive care (22%), platinum-based salvage therapy (13%), low-intensity chemotherapy (22%), in clinical trial (14%) or various combination treatments (32%). The 2-year OS-/PFS estimates were 25% and 12% for all patients and 49% and 17% for those treated with platinum-based salvage therapy. Age ≥70, CNS involvement, elevated LDH and ECOG ≥2 predicted poor outcomes, and patients with 0–1 of these risk factors had a 2-year OS estimate of 65%. Only a very small fraction of DLBCL patients received third-line treatment and were eligible for inclusion. Outcomes were generally poor, but better in intensively treated, fit young patients with limited disease., Outcome data of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) beyond the second line are scarce outside of clinical trials. Novel therapies in the R/R setting have been approved based on single-arm trials, but results need to be contextualized by real-world outcomes. Medical records from 3753 Danish adults diagnosed with DLBCL were reviewed. Patients previously treated with rituximab and anthracycline-based chemotherapy who received the third or later line (3 L+) of treatment after 1 January 2015, were included. Only 189 patients with a median age of 71 years were eligible. The median time since the last line of therapy was 6 months. Patients were treated with either best supportive care (22%), platinum-based salvage therapy (13%), low-intensity chemotherapy (22%), in clinical trial (14%) or various combination treatments (32%). The 2-year OS-/PFS estimates were 25% and 12% for all patients and 49% and 17% for those treated with platinum-based salvage therapy. Age ≥70, CNS involvement, elevated LDH and ECOG ≥2 predicted poor outcomes, and patients with 0–1 of these risk factors had a 2-year OS estimate of 65%. Only a very small fraction of DLBCL patients received third-line treatment and were eligible for inclusion. Outcomes were generally poor, but better in intensively treated, fit young patients with limited disease.

Published
2024

34. Risk of dementia among older patients with lymphoma:A Danish nationwide matched cohort study

Author

Maksten, Eva Futtrup, Jakobsen, Lasse Hjort, Modrau, Boris, Jensvoll, Hilde, Kragholm, Kristian Hay, Jørgensen, Judit Mészáros, Clausen, Michael Roost, Pedersen, Robert Schou, Dessau-Arp, Andriette, Larsen, Thomas Stauffer, Poulsen, Christian Bjørn, Gang, Anne Ortved, Brown, Peter, El-Galaly, Tarec C., Severinsen, Marianne Tang, Maksten, Eva Futtrup, Jakobsen, Lasse Hjort, Modrau, Boris, Jensvoll, Hilde, Kragholm, Kristian Hay, Jørgensen, Judit Mészáros, Clausen, Michael Roost, Pedersen, Robert Schou, Dessau-Arp, Andriette, Larsen, Thomas Stauffer, Poulsen, Christian Bjørn, Gang, Anne Ortved, Brown, Peter, El-Galaly, Tarec C., and Severinsen, Marianne Tang

Abstract

Introduction Treatment of lymphoma can be associated with cognitive challenges, and some patients may fear development of dementia as long-term complication. Studies report a lower risk of dementia after cancer. Some believe this difference to be a protective mechanism of cancer, others believe it to be driven by bias. The risk of developing dementia after lymphoma has not been investigated in a population-based setting. The aim of this study was to identify the risk of being diagnosed with dementia after lymphoma treatment. Materials and Methods This Danish nationwide matched cohort study included patients aged ≥65 years with a first-time diagnosis of a non-central nervous system lymphoma between 2005 and 2018 in complete remission after treatment with chemotherapy. Patients diagnosed with dementia or treated with dementia medication before lymphoma diagnosis were excluded. Each patient was matched 1:5 on sex, year of birth, and a modified Charlson comorbidity index. Patients and matched comparators were followed from the corresponding patient's date of complete remission. The risk of developing dementia was calculated using cause-specific hazard ratios (HR), and the cumulative risk was estimated by Aalen-Johansen with death as the competing risk. Results A total of 3,244 patients and 16,220 matched comparators were included in the study. There was no difference in risk of all-cause dementia among patients with lymphoma compared to matched comparators with cause-specific HR of 0.85 (95% confidence interval [CI]: 0.70;1.04). The risk of both Alzheimer's disease and non-Alzheimer's dementia was equal among patients and comparators: HR 0.89 (95% CI: 0.66;1.21) and 0.82 (95% CI: 0.63;1.07), respectively. Stratified by lymphoma subtype, age, or year of diagnosis, the risk of all-cause dementia remained equal among patients and matched comparators. The cumulative risk of all-cause dementia was significantly lower among patients with lymphoma, Introduction: Treatment of lymphoma can be associated with cognitive challenges, and some patients may fear development of dementia as long-term complication. Studies report a lower risk of dementia after cancer. Some believe this difference to be a protective mechanism of cancer, others believe it to be driven by bias. The risk of developing dementia after lymphoma has not been investigated in a population-based setting. The aim of this study was to identify the risk of being diagnosed with dementia after lymphoma treatment. Materials and Methods: This Danish nationwide matched cohort study included patients aged ≥65 years with a first-time diagnosis of a non-central nervous system lymphoma between 2005 and 2018 in complete remission after treatment with chemotherapy. Patients diagnosed with dementia or treated with dementia medication before lymphoma diagnosis were excluded. Each patient was matched 1:5 on sex, year of birth, and a modified Charlson comorbidity index. Patients and matched comparators were followed from the corresponding patient's date of complete remission. The risk of developing dementia was calculated using cause-specific hazard ratios (HR), and the cumulative risk was estimated by Aalen-Johansen with death as the competing risk. Results: A total of 3,244 patients and 16,220 matched comparators were included in the study. There was no difference in risk of all-cause dementia among patients with lymphoma compared to matched comparators with cause-specific HR of 0.85 (95% confidence interval [CI]: 0.70;1.04). The risk of both Alzheimer's disease and non-Alzheimer's dementia was equal among patients and comparators: HR 0.89 (95% CI: 0.66;1.21) and 0.82 (95% CI: 0.63;1.07), respectively. Stratified by lymphoma subtype, age, or year of diagnosis, the risk of all-cause dementia remained equal among patients and matched comparators. The cumulative risk of all-cause dementia was significantly lower among patients with lymphoma compared to matched com

Published
2024

35. Nutrition and lifestyle-related factors as predictors of muscle atrophy in hematological cancer patients

Author

Staxen, Christiane S, Andersen, Sara E, Pedersen, Lars Møller, Poulsen, Christian Bjørn, Andersen, Jens Rikardt, Staxen, Christiane S, Andersen, Sara E, Pedersen, Lars Møller, Poulsen, Christian Bjørn, and Andersen, Jens Rikardt

Abstract

Background: Cancer and side effects from cytostatic treatment commonly affect nutritional status manifested as a decrease in muscle mass. We aimed to investigate the impact of nutrition and lifestyle-related factors on muscle mass in patients with hematological cancer. Methods: Dietary intake, food preferences, quality of life (QoL), and physical activity level (PAL) were monitored during 1–2 cytostatic treatment series. Body composition was estimated using bioelectrical impedance analysis (BIA). Results: 61 patients were included. Weight loss and loss of muscle mass were detected in 64% and 59% of the patients, respectively. Muscle mass was significantly positively correlated to increasing PAL (p = 0.003), while negatively correlated to increasing age (p = 0.03), physical QoL (p = 0.007), functional QoL (p = 0.05), self-perceived health (p = 0.004), and self-perceived QoL (p = 0.007). Weight was significantly positively correlated to increased intake of soft drinks (p = 0.02) as well as the favoring of bitter grain and cereal products (p = 0.03), while negatively correlated to increasing age (p = 0.03) and increasing meat intake (p = 0.009) Conclusions: Several nutritional and lifestyle-related factors affected change in body composition. The clinical significance of these changes should be investigated in controlled, interventional studies.

Published
2024

36. Complex Regulation of Prolyl-4-Hydroxylases Impacts Root Hair Expansion

Author

Velasquez, Silvia M, Ricardi, Martiniano M, Poulsen, Christian Peter, Oikawa, Ai, Dilokpimol, Adiphol, Halim, Adnan, Mangano, Silvina, Juarez, Silvina Paola Denita, Marzol, Eliana, Salter, Juan D Salgado, Dorosz, Javier Gloazzo, Borassi, Cecilia, Möller, Svenning Rune, Buono, Rafael, Ohsawa, Yukiko, Matsuoka, Ken, Otegui, Marisa S, Scheller, Henrik V, Geshi, Naomi, Petersen, Bent Larsen, Iusem, Norberto D, and Estevez, José M

Subjects
Biochemistry and Cell Biology, Biological Sciences, Arabidopsis, Arabidopsis Proteins, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Plant, Glycosylation, Hydroxylation, Hydroxyproline, Multigene Family, Plant Roots, Prolyl Hydroxylases, enzymology, cell expansion, cell walls, protein targeting, proline hydroxylation, root hairs, Genetics, Plant Biology, Plant Biology & Botany, Biochemistry and cell biology, Plant biology
Abstract

Root hairs are single cells that develop by tip growth, a process shared with pollen tubes, axons, and fungal hyphae. However, structural plant cell walls impose constraints to accomplish tip growth. In addition to polysaccharides, plant cell walls are composed of hydroxyproline-rich glycoproteins (HRGPs), which include several groups of O-glycoproteins, including extensins (EXTs). Proline hydroxylation, an early post-translational modification (PTM) of HRGPs catalyzed by prolyl 4-hydroxylases (P4Hs), defines their subsequent O-glycosylation sites. In this work, our genetic analyses prove that P4H5, and to a lesser extent P4H2 and P4H13, are pivotal for root hair tip growth. Second, we demonstrate that P4H5 has in vitro preferred specificity for EXT substrates rather than for other HRGPs. Third, by P4H promoter and protein swapping approaches, we show that P4H2 and P4H13 have interchangeable functions but cannot replace P4H5. These three P4Hs are shown to be targeted to the secretory pathway, where P4H5 forms dimers with P4H2 and P4H13. Finally, we explore the impact of deficient proline hydroxylation on the cell wall architecture. Taken together, our results support a model in which correct peptidyl-proline hydroxylation on EXTs, and possibly in other HRGPs, is required for proper cell wall self-assembly and hence root hair elongation in Arabidopsis thaliana.

Published
2015

37. Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark

Author

Jakobsen, Lasse Hjort, Øvlisen, Andreas Kiesbye, Severinsen, Marianne Tang, Bæch, Joachim, Kragholm, Kristian Hay, Glimelius, Ingrid, Gang, Anne Ortved, Jørgensen, Judit Mészáros, Frederiksen, Henrik, Poulsen, Christian Bjørn, Clausen, Michael Roost, Pedersen, Per Trøllund, Pedersen, Robert Schou, Torp-Pedersen, Christian, Eloranta, Sandra, and El-Galaly, Tarec Christoffer

Published
2022
Full Text
View/download PDF

39. Treatment of the elderly patient with haematological cancer

Author

Andersen, Nina, primary, Al-Mashadi, Ahmed Ludvigsen, additional, Rotbain, Emelie Hamotal Curovic, additional, Kristensen, Ida Bruun, additional, Lauritsen, Tine Bichel, additional, Poulsen, Christian Bjørn, additional, Ommen, Hans Beier, additional, Andersen, Christen Bertel Lykkegaard, additional, El-Galaly, Tarec Christoffer, additional, and Abildgaard, Niels, additional

Published
2024
Full Text
View/download PDF

43. Revisiting beta‐2 microglobulin as a prognostic marker in diffuse large B‐cell lymphoma.

Author

Jelicic, Jelena, Juul‐Jensen, Karen, Bukumiric, Zoran, Runason Simonsen, Mikkel, Roost Clausen, Michael, Ludvigsen Al‐Mashhadi, Ahmed, Schou Pedersen, Robert, Bjørn Poulsen, Christian, Ortved Gang, Anne, Brown, Peter, El‐Galaly, Tarec Christoffer, and Larsen, Thomas Stauffer

Subjects
PROGNOSIS, DIFFUSE large B-cell lymphomas, DISEASE risk factors, OVERALL survival, PROGNOSTIC models
Abstract

Background: Several clinical prognostic models for diffuse large B‐cell lymphoma (DLBCL) have been proposed, including the most commonly used International Prognostic Index (IPI), the National Comprehensive Cancer Network IPI (NCCN‐IPI), and models incorporating beta‐2 microglobulin (β2M). However, the role of β2M in DLBCL patients is not fully understood. Methods: We identified 6075 patients with newly diagnosed DLBCL treated with immunochemotherapy registered in the Danish Lymphoma Registry. Results: A total of 3232 patients had data available to calculate risk scores from each of the nine considered risk models for DLBCL, including a model developed from our population. Three of four models with β2M and NCCN‐IPI performed better than the International Prognostic Indexes (IPI, age‐adjusted IPI, and revised IPI). Five‐year overall survival for high‐ and low‐risk patients were 43.6% and 86.4% for IPI and 34.9% and 96.2% for NCCN‐IPI. In univariate analysis, higher levels of β2M were associated with inferior survival, higher tumor burden (advanced clinical stage and bulky disease), previous malignancy and increased age, and creatinine levels. Furthermore, we developed a model (β2M‐NCCN‐IPI) by adding β2M to NCCN‐IPI (c‐index 0.708) with improved discriminatory ability compared to NCCN‐IPI (c‐index 0.698, p < 0.05) and 5‐year OS of 33.1%, 56.2%, 82.4%, and 96.4% in the high, high‐intermediate, low‐intermediate and low‐risk group, respectively. Conclusion: International Prognostic Indices, except for NCCN‐IPI, fail to accurately discriminate risk groups in the rituximab era. β2M, a readily available marker, could improve the discriminatory performance of NCCN‐IPI and should be re‐evaluated in the development setting of future models for DLBCL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry

Author

Musto, Pellegrino, primary, Salmanton‐García, Jon, additional, Sgherza, Nicola, additional, Bergantim, Rui, additional, Farina, Francesca, additional, Glenthøj, Andreas, additional, Cengiz Seval, Guldane, additional, Weinbergerová, Barbora, additional, Bonuomo, Valentina, additional, Bilgin, Yavuz M., additional, van Doesum, Jaap, additional, Jaksic, Ozren, additional, Víšek, Benjamín, additional, Falces‐Romero, Iker, additional, Marchetti, Monia, additional, Dávila‐Valls, Julio, additional, Martín‐Pérez, Sonia, additional, Nucci, Marcio, additional, López‐García, Alberto, additional, Itri, Federico, additional, Buquicchio, Caterina, additional, Verga, Luisa, additional, Piukovics, Klára, additional, Navrátil, Milan, additional, Collins, Graham P., additional, Jiménez, Moraima, additional, Fracchiolla, Nicola S., additional, Labrador, Jorge, additional, Prezioso, Lucia, additional, Rossi, Elena, additional, Čolović, Natasha, additional, Meers, Stef, additional, Kulasekararaj, Austin, additional, Cuccaro, Annarosa, additional, Blennow, Ola, additional, Valković, Toni, additional, Sili, Uluhan, additional, Ledoux, Marie‐Pierre, additional, Batinić, Josip, additional, Passamonti, Francesco, additional, Machado, Marina, additional, Duarte, Rafael F., additional, Poulsen, Christian Bjørn, additional, Méndez, Gustavo‐Adolfo, additional, Espigado, Ildefonso, additional, Demirkan, Fatih, additional, Čerňan, Martin, additional, Cattaneo, Chiara, additional, Petzer, Verena, additional, Magliano, Gabriele, additional, Garcia‐Vidal, Carolina, additional, El‐Ashwah, Shaimaa, additional, Gomes‐Da‐Silva, Maria, additional, Vena, Antonio, additional, Ormazabal‐Vélez, Irati, additional, van Praet, Jens, additional, Dargenio, Michelina, additional, De‐Ramón, Cristina, additional, Del Principe, Maria Ilaria, additional, Marques‐De‐Almeida, Joyce, additional, Wolf, Dominik, additional, Szotkowski, Tomáš, additional, Obr, Aleš, additional, Çolak, Gökçe Melis, additional, Nordlander, Anna, additional, Izuzquiza, Macarena, additional, Cabirta, Alba, additional, Zambrotta, Giovanni Paolo Maria, additional, Cordoba, Raul, additional, Žák, Pavel, additional, Ammatuna, Emanuele, additional, Mayer, Jiří, additional, Ilhan, Osman, additional, García‐Sanz, Ramón, additional, Quattrone, Martina, additional, Arellano, Elena, additional, Nunes‐Rodrigues, Raquel, additional, Emarah, Ziad, additional, Aiello, Tommaso Francesco, additional, Hanakova, Michaela, additional, Ráčil, Zdeněk, additional, Bavastro, Martina, additional, Limongelli, Alessandro, additional, Rahimli, Laman, additional, Marchesi, Francesco, additional, Cornely, Oliver A., additional, and Pagano, Livio, additional

Published
2023
Full Text
View/download PDF

46. Real‐world outcomes following third or subsequent lines of therapy: A Danish population‐based study on 189 patients with relapsed/refractory large B‐cell lymphomas

Author

AL‐Mashhadi, Ahmed Ludvigsen, primary, Jakobsen, Lasse Hjort, additional, Brown, Peter, additional, Gang, Anne Ortved, additional, Thorsteinsson, Anne‐Luise, additional, Rasoul, Kaziwa, additional, Haissman, Judith Melchior, additional, Tøstesen, Michael Buch, additional, Christoffersen, Mette Niemann, additional, Jelicic, Jelena, additional, Jørgensen, Jennifer Bøgh, additional, Thomsen, Troels, additional, Dessau‐Arp, Andriette, additional, Andersen, Andreas P. H., additional, Frederiksen, Mikael, additional, Pedersen, Per Trøllund, additional, Clausen, Michael Roost, additional, Jørgensen, Judit Meszaros, additional, Poulsen, Christian Bjørn, additional, El‐Galaly, Tarec Christoffer, additional, and Larsen, Thomas Stauffer, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results